



## Clinical Outcomes and Safety Profile of Standalone Canaloplasty Vs. Canaloplasty Combined with Cataract Surgery Using iTrack Microcatheter

*Paper*

**Authors:** Mary Qiu, MD; Nathan M Kerr, MD; Keith Barton, MD; Shamil Patel, MD; David M. Lubeck, MD



**Purpose:** To evaluate the clinical outcomes and safety profile of standalone ab-interno canaloplasty performed using the iTrack microcatheter (Nova Eye Medical) compared to ab-interno canaloplasty combined with cataract surgery.

**Method:** Data were collected from the prospective multicenter cloud-based database (iTGDR, part of the International Glaucoma Surgery Registry – IGSR), including eyes with glaucoma diagnosis and 12 months of follow-up. Patients underwent canaloplasty using the ab-interno technique with the iTrack or iTrack Advance (Nova Eye Inc., Fremont, USA), either as a standalone procedure (standalone group) or combined with cataract surgery (+phaco group). All glaucoma types were included except for angle closure glaucoma.

**Results:** In the standalone canaloplasty group (37 eyes; n=28 phakic, n=9 pseudophakic) baseline IOP (mmHg) and medications significantly decreased from  $20.8 \pm 6.5$  and  $2.32 \pm 0.88$  to  $15.6 \pm 7.20$  (-25.3%;  $p=0.015$ ) and  $1.19 \pm 1.38$  (-48.9%;  $p=0.008$ ) at 12 months (n=16). In the canaloplasty +phaco group (338 eyes) IOP and number of medications significantly decreased from  $17.4 \pm 5.8$  and  $2.01 \pm 1.17$  to  $13.81 \pm 3.54$  (-20.7%;  $p<0.001$ ) and  $0.79 \pm 1.21$  (-60.9%;  $p<0.001$ ) at 12 months (n=122). In the phakic eyes standalone group the reduction in IOP and medications was significant ( $p=0.022$ ;  $p=0.02$ ); there were not enough standalone pseudophakic eyes to return a meaningful p value. No serious adverse events were recorded.

**Conclusions:** Both standalone canaloplasty and canaloplasty combined with cataract surgery using the iTrack microcatheter significantly reduced intraocular pressure and the number of medications over a 12-month period, with no serious adverse events observed.

**Disclosures:** The authors have no financial and proprietary interests to disclose about the product(s) mentioned in this abstract. They are consultants to Nova Eye Medical

Saturday, April 26  
Minimally Invasive Glaucoma Surgery (MIGS) II  
2:05 PM - 2:10 PM  
LACC - Meeting Room Level 2, 513